3594 Background: BV associated with chemotherapy has been demonstrated to improve overall survival (OS) in metastatic CRC (mCRC). This allows to consider secondary resection of metastases for the initially unresectable mCRC. Methods: ETNA is a cohort study conducted in 28 French centers. It included patients (pts) initiating BV from Jan 2006 to Dec 2007. Those treated in first-line therapy for mCRC were followed for 24 months. Effectiveness for pats with secondary resection of metastases and curative intent is presented here. Results: A total of 411 pts had first-line therapy with BV for mCRC: 347 were analyzable after 24 months of follow-up, and 67 (19.3%) had metastasis resection (pts operated, oPts). oPts main baseline characteristics were: mean age: 61.6 y, male: 46.3%, ECOG 0-1: 91.0% and one metastatic site: 58.2%; those of not operated pts (noPts) were: mean age: 64.0 y, male: 60.0%, ECOG 0-1: 77.5% and one metastatic site: 55.7%. Among the oPts, resection site was: liver n = 44, lung n = 10, other n = 20. Results of surgery available for 56 oPts were: R0-R1: 85.7%, R2: 14.3%. The median time from BV initiation to first resection was 207 days. For oPts, BV was mainly associated with irinotecan-based regimens (97.0%) and with FOLFOX regimens (3.0%); for noPts it was: FOLFIRI: 83.6%, XELIRI: 2.9%, FOLFOX: 10.7%, XELOX: 2.5% and FOLFIRINOX: 0.4%. Objective response rate was 85.1% including 32.8% complete response (vs. 49.3% and 5.4% for noPts), stable disease 14.9% (vs. 30.0%) and absence of progressive disease (vs. 17.1%). Median duration of BV treatment was 6.9 months and of first-line therapy was 14.3 months (vs. 5.0 and 8.3 months for noPts). Median PFS was 13.6 months for oPts, the 1-yr OS rate was 94.0% (95%CI 84.9-97.7) and the 2-yr OS rate was 81.7% (95%CI 70.0-89.2) (vs. for noPts: median PFS 9.0 months, 1-yr OS rate 75.2% [95%CI 69.6-79.8] and the 2-yr OS rate 44.5% [95%CI 38.5-50.4]). Median OS was not reached for oPts and was 21.9 months for noPts. Conclusions: For pts treated by BV in a real-life setting, secondary resection of mCRC for initially unresectable metastases was possible for 19% of pts with 85.7% R0-R1. Evaluation of morbidity and longer follow-up will allow the real long-term benefit to be studied. No significant financial relationships to disclose.